Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD.

Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.


Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.

van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD.

Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21.


Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.

van den Hout MF, Sluijter BJ, Santegoets SJ, van Leeuwen PA, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2016 Apr;65(4):405-15. doi: 10.1007/s00262-016-1811-z. Epub 2016 Mar 2.


Total number of lymph nodes in oncologic resections, is there more to be found?

de Burlet KJ, van den Hout MF, Putter H, Smit VT, Hartgrink HH.

J Gastrointest Surg. 2015 May;19(5):943-8. doi: 10.1007/s11605-015-2764-9. Epub 2015 Feb 18.


Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.


Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation.

van de Ven R, van den Hout MF, Lindenberg JJ, Sluijter BJ, van Leeuwen PA, Lougheed SM, Meijer S, van den Tol MP, Scheper RJ, de Gruijl TD.

Blood. 2011 Sep 1;118(9):2502-10. doi: 10.1182/blood-2011-03-344838. Epub 2011 Jul 12.


Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.

van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM.

J Clin Oncol. 2011 Jun 1;29(16):2206-14. doi: 10.1200/JCO.2010.31.6760. Epub 2011 Apr 25.


4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.

Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, van den Tol MP, van Leeuwen PA, Meijer S, Scheper RJ, June CH, de Gruijl TD, Santegoets SJ.

Clin Immunol. 2010 Nov;137(2):221-33. doi: 10.1016/j.clim.2010.07.009. Epub 2010 Aug 13.


Supplemental Content

Loading ...
Support Center